Funding for medical education: Maintaining a healthy separation from industry

Circulation

Volumn 121, Issue 20, 2010, Pages 2228-2234

  Avorn, Jerry ^a   Choudhry, Niteesh K ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARDIOLOGY; CONTINUING EDUCATION; FUNDING; MEDICAL EDUCATION; MEDICAL PRACTICE; NOTE; PHYSICIAN; PRIORITY JOURNAL;

CAPITAL FINANCING; CONFLICT OF INTEREST; EDUCATION, MEDICAL; INDUSTRY;

EID: 77953004524     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.109.869636     Document Type: Note

References (44)

1. Ariely D. Predictably Irrational. New York, NY: Harper Collins; 2009.
2. Avorn J. Powerful Medicines: The Benefits, Risks, and Costs of Prescription Drugs. New York, NY: Knopf; 2004.
3. Steinbrook R. Financial support of continuing medical education. JAMA. 2008;299:1060-1062.
4. Association of American Medical Colleges. Annual report data 2008. Availableat: http://www.accme.org/dir-docs/doc-upload/1f8dc476-246a-4e8e-91d3- d24ff2f5bfec-uploaddocument.pdf. Accessed June 28, 2009.
5. Josiah Macy Junior Foundation. Continuing education in the health professions: improving healthcare through lifelong learning 2008. Available at: http://www.josiahmacyfoundation.org. Accessed June 28, 2009.
6. Wang SS. Pfizer stops funding some classes for doctors. Wall Street Journal. July 2, 2008. Available at: http://blogs.wsj.com/health/2008/07/02/ pfizer-stops-funding-some-classes-for-doctors. Accessed June 28, 2009.
7. Prosser H, Almond S, Walley T. Influences on GPs' decision to prescribe new drugs: the importance of who says what. Fam Pract. 2003;20:61-68.
8. Campbell EG, Gruen RL, Mountford J, Miller LG, Cleary PD, Blu-menthal D. A national survey of physician-industry relationships. N Engl J Med. 2007;356:1742-1750.
9. Steinman MA, Bero LA, Chren MM, Landefeld CS. Narrative review: the promotion of gabapentin: an analysis of internal industry documents. Ann Intern Med. 2006;145:284-293.
10. The Scientific Basis of Influence and Reciprocity: A Symposium: June 12, 2007. Washington, DC: Association of American Medical Colleges; 2007.
11. Bowman MA, Pearle DL. Changes in drug prescribing patterns related to commercial company funding of continuing medical education. J Contin Educ Health Prof. 1988;8:13-20.
12. Wazana A. Physicians and the pharmaceutical industry: is a gift ever just a gift? JAMA. 2000;283:373-380. (Pubitemid 30051756)
13. Bowman MA. The impact of drug company funding on the content of continuing medical education. Mobius. 1986;6:66-69.
14. Chren MM, Landefeld CS. Physicians' behavior and their interactions with drug companies: a controlled study of physicians who requested additions to a hospital drug formulary. JAMA. 1994;271:684-689.
15. Sondergaard J, Vach K, Kragstrup J, Andersen M. Impact of pharmaceutical representative visits on GPs' drug preferences. Fam Pract. 2009; 26:204-209.
16. Caudill TS, Johnson MS, Rich EC, McKinney WP. Physicians, pharmaceutical sales representatives, and the cost of prescribing. Arch Fam Med. 1996;5:201-206.
17. Haayer F. Rational prescribing and sources of information. Soc Sci Med. 1982;16:2017-2023.
18. Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K, Lines C, Riddell R, Morton D, Lanas A, Konstam MA, Baron JA; the Adenomatous Polyp Prevention on Vioxx Trial Investigators. Cardiovascular events associated with rofecoxib in a colorectal adenoma che-moprevention trial. N Engl J Med. 2005;352:1092-1102.
19. Curfman GD, Morrissey S, Drazen JM. Expression of concern: Bombardier et al, "Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis." N Engl J Med. 2000;343:1520-8.
20. N Engl J Med. 2005;353:2813-2814.
21. Berenson A. For Merck, Vioxx paper trail won't go away. New York Times. August 21, 2005:A1.
22. Mundy A. Doctors claim Glaxo stifled their worries on Avandia. Wall Street Journal. November 19, 2008:B1.
23. Meier B. Medtronic links device for heart to 13 deaths. New York Times. March 13, 2009:B1.
24. National Institutes of Health. The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure
25. Singer N. Merck paid for medical "journal" without disclosure. New York Times. May 13, 2009. Available at: http://www.nytimes.com/2009/05/14/ business/14vioxxside.html?scp= 1&sq = Merck%20Paid%20for%20 Medical%20'Journal'%20Without%20Disclosure&st=cseIt. Accessed June 28, 2009.
26. Choudhry NK, Stelfox HT, Detsky AS. Relationships between authors of clinical practice guidelines and the pharmaceutical industry. JAMA. 2002; 287:612-617.
27. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vit-tinghoff E; Heart and Estrogen/progestin Replacement Study (HERS) Research Group. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA. 1998;280:605-613
28. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative Randomized Controlled Trial. JAMA. 2002;288:321-333.
29. Singer N. Medical papers by ghostwriters pushed therapy. New York Times. August 4, 2009:A1.
30. Singer N, Wilson D. Menopause, as brought to you by big pharma. New York Times. December 12, 2009:BU1.
31. Knowing what works in health care: a roadmap for the nation. Washington, DC: Institute of Medicine; 2008. Available at: http://www.nap. edu. Accessed June 28 2009.
32. Conflict of interest in medical research, education, and practice. Washington, DC; Institute of Medicine; 2009. Available at: http://www.nap. edu. Accessed June 28 2009.
33. Coyne DW. Influence of industry on renal guideline development. Clin J Am Soc Nephrol. 2007;2:3-7.
34. Singh AK, SzczechL, Tang KL, BarnhartH, SappS, WolfsonM, Reddan D. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006;355:2085-2098.
35. Association of American Medical Colleges. Industry funding of medical education 2008. Available at: http://services.aamc.org/publications/showfile. cfm?file = version114.pdf&prd-id = 232&prv-id=281&pdf- id= 114. Accessed June 28, 2009.
36. Brennan TA, Rothman DJ, Blank L, Blumenthal D, Chimonas SC, Cohen JJ, Goldman J, Kassirer JP, Kimball H, Naughton J, Smelser N. Health industry practices that create conflicts of interest: a policy proposal for academic medical centers. JAMA. 2006;295:429-433.
37. Goldblum OM, Franzblau MJ. Academic medical centers and conflicts of interest. JAMA. 2006;295:2845-2846, author reply 2848-2849.
38. Stanford School of Medicine. New policy on continuing medical education 2008. Available at: http://med.stanford.edu/coi/documents/deanpizzo-cmeletter. pdf. Accessed June 29, 2009.
39. Wilson D. Using a Pfizer grant, courses aim to avoid bias. New York Times. January 11, 2010:B4.
40. University of Pittsburgh Schools of the Health Sciences. Industry relationship policy 2009. Available at: http://www.coi.pitt.edu/ IndustryRelationships/policy.htm. Accessed June 29, 2009.
41. Goldstein J. How Sloan-Kettering kicked educational drug money habit. February 7. Available at: http://blogs.wsj.com/health/2008/02/07/how-sloan- kettering-kicked-educational-drug-money-habit/. Accessed June 29, 2009.
42. Avorn J, Soumerai SB. Improving drug-therapy decisions through educational outreach: a randomized controlled trial of academically based "detailing." N Engl J Med. 1983;308:1457-1463.
43. Avorn J, Soumerai SB, Everitt DE, Ross-Degnan D, Beers MH, Sherman D, Salem-Schatz SR, Fields D. A randomized trial of a program to reduce the use of psychoactive drugs in nursing homes. N Engl J Med. 1992; 327:168-173.
44. O'Brien MA, Rogers S, Jamtvedt G, Oxman Andrew D, Odgaard-Jensen J, Kristoffersen DT, Forsetlund L, Bainbridge D, Freemantle N, Davis D, Haynes RB, Harvey E. Educational outreach visits: effects on professional practice and health care outcomes. Cochrane Database of Systematic Reviews. Chichester, UK: John Wiley & Sons, Ltd; 2007 Oct 17:CD000409.